Efficacy of Tocilizumab in Patients with COVID-19
Background and purpose: Tocilizumab (TCZ), a monoclonal antibody against interleukin-6 (IL-6) receptor, is emerged as an alternative treatment for COVID-19 patients with a risk of cytokine storms. This study aimed at investigating the efficacy of TCZ in patients with COVID-19. Materials and methods:...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mazandaran University of Medical Sciences
2022-12-01
|
| Series: | Journal of Mazandaran University of Medical Sciences |
| Subjects: | |
| Online Access: | http://jmums.mazums.ac.ir/article-1-18510-en.html |
| _version_ | 1797893136397107200 |
|---|---|
| author | Ahmad Alikhani Zahra Nekoukar Minoo Moghimi Maysam Rezapour Seyyed Javad Boskabadi Amir Mohammad Shabani Hamideh Abbaspour Kasgari |
| author_facet | Ahmad Alikhani Zahra Nekoukar Minoo Moghimi Maysam Rezapour Seyyed Javad Boskabadi Amir Mohammad Shabani Hamideh Abbaspour Kasgari |
| author_sort | Ahmad Alikhani |
| collection | DOAJ |
| description | Background and purpose: Tocilizumab (TCZ), a monoclonal antibody against interleukin-6 (IL-6) receptor, is emerged as an alternative treatment for COVID-19 patients with a risk of cytokine storms. This study aimed at investigating the efficacy of TCZ in patients with COVID-19.
Materials and methods: In a retrospective observational study, we examined the demographic and clinical characteristics of patients with COVID-19 and also the outcomes of TCZ therapy (Actemra® and Temziva®) in Qaemshahr Razi Hospital.
Results: Out of 56 cases, 32 (57.1%) were women and the median age of the patients was 57.5 years. Among the patients, 19 (33.9%) were admitted to ICU where seven (12.7%) were intubated and eight (14.3%) patients deceased. Before TCZ therapy, mean oxygen saturation level was 90.1% which elevated to 93.8% after receiving TCZ (P=0.001). In this study, Temziva® was associated with lower mortality rate compared with Actemra® (P=0.004).
Conclusion: TCZ therapy in patients with COVID-19 could improve oxygen saturation level and Temziva® results in lower mortality rate. However, further studies with larger sample size are required to confirm these results. |
| first_indexed | 2024-04-10T06:48:06Z |
| format | Article |
| id | doaj.art-2375a79d313649439bacab1ec3c2d7a2 |
| institution | Directory Open Access Journal |
| issn | 1735-9260 1735-9279 |
| language | English |
| last_indexed | 2024-04-10T06:48:06Z |
| publishDate | 2022-12-01 |
| publisher | Mazandaran University of Medical Sciences |
| record_format | Article |
| series | Journal of Mazandaran University of Medical Sciences |
| spelling | doaj.art-2375a79d313649439bacab1ec3c2d7a22023-02-28T09:18:48ZengMazandaran University of Medical SciencesJournal of Mazandaran University of Medical Sciences1735-92601735-92792022-12-0132215163168Efficacy of Tocilizumab in Patients with COVID-19Ahmad Alikhani0Zahra Nekoukar1Minoo Moghimi2Maysam Rezapour3Seyyed Javad Boskabadi4Amir Mohammad Shabani5Hamideh Abbaspour Kasgari6 Associate Professor, Antimicrobial Resistance Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran Clinical Pharmacy Resident, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran Clinical Pharmacy Resident, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran Assistant Professor, Department of Paramedicine, Amol Faculty of Paramedical Sciences, Mazandaran University of Medical Sciences, Sari, Iran. Clinical Pharmacy Resident, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran Clinical Pharmacy Resident, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran Assistant Professor, Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran Background and purpose: Tocilizumab (TCZ), a monoclonal antibody against interleukin-6 (IL-6) receptor, is emerged as an alternative treatment for COVID-19 patients with a risk of cytokine storms. This study aimed at investigating the efficacy of TCZ in patients with COVID-19. Materials and methods: In a retrospective observational study, we examined the demographic and clinical characteristics of patients with COVID-19 and also the outcomes of TCZ therapy (Actemra® and Temziva®) in Qaemshahr Razi Hospital. Results: Out of 56 cases, 32 (57.1%) were women and the median age of the patients was 57.5 years. Among the patients, 19 (33.9%) were admitted to ICU where seven (12.7%) were intubated and eight (14.3%) patients deceased. Before TCZ therapy, mean oxygen saturation level was 90.1% which elevated to 93.8% after receiving TCZ (P=0.001). In this study, Temziva® was associated with lower mortality rate compared with Actemra® (P=0.004). Conclusion: TCZ therapy in patients with COVID-19 could improve oxygen saturation level and Temziva® results in lower mortality rate. However, further studies with larger sample size are required to confirm these results.http://jmums.mazums.ac.ir/article-1-18510-en.htmltocilizumabil6covid-19cytokine storm |
| spellingShingle | Ahmad Alikhani Zahra Nekoukar Minoo Moghimi Maysam Rezapour Seyyed Javad Boskabadi Amir Mohammad Shabani Hamideh Abbaspour Kasgari Efficacy of Tocilizumab in Patients with COVID-19 Journal of Mazandaran University of Medical Sciences tocilizumab il6 covid-19 cytokine storm |
| title | Efficacy of Tocilizumab in Patients with COVID-19 |
| title_full | Efficacy of Tocilizumab in Patients with COVID-19 |
| title_fullStr | Efficacy of Tocilizumab in Patients with COVID-19 |
| title_full_unstemmed | Efficacy of Tocilizumab in Patients with COVID-19 |
| title_short | Efficacy of Tocilizumab in Patients with COVID-19 |
| title_sort | efficacy of tocilizumab in patients with covid 19 |
| topic | tocilizumab il6 covid-19 cytokine storm |
| url | http://jmums.mazums.ac.ir/article-1-18510-en.html |
| work_keys_str_mv | AT ahmadalikhani efficacyoftocilizumabinpatientswithcovid19 AT zahranekoukar efficacyoftocilizumabinpatientswithcovid19 AT minoomoghimi efficacyoftocilizumabinpatientswithcovid19 AT maysamrezapour efficacyoftocilizumabinpatientswithcovid19 AT seyyedjavadboskabadi efficacyoftocilizumabinpatientswithcovid19 AT amirmohammadshabani efficacyoftocilizumabinpatientswithcovid19 AT hamidehabbaspourkasgari efficacyoftocilizumabinpatientswithcovid19 |